Abstract
In this educational post, I walk you through a comprehensive, evidence-based overview of hormone optimization with a special focus on estrogen, progesterone, and testosterone across the lifespan. I explain why disease is not a normal state and how restoring homeostasis requires moving beyond an allopathic symptom-suppression mindset. You will find an in-depth discussion of the latest data that overturns long-held misconceptions from earlier trials, including clear distinctions between bioidentical hormones and synthetic progestins. I also unpack the physiology of hormone receptors across tissues, showing how estradiol supports brain plasticity, cognition, stroke mitigation, spinal and peripheral injury recovery, lipid balance, and atherosclerosis reduction. The latter portion explores metabolic health and the clinical nuts and bolts of diabetes care with targeted protocols. Finally, I present pragmatic clinical decision-making: why we individualize therapy duration, dosing, and routes; how and when to initiate therapy at different ages; and why abrupt discontinuation is unwise. Along the way, I integrate my practice observations from El Paso and link out to ongoing work and case narratives. If you care for patients with midlife symptoms, cognitive decline, pain syndromes, cardiovascular risk, metabolic disease, or are weighing hormone therapy after breast cancer, this post consolidates modern data and provides rationale-driven clinical guidance.
Highlights
Why abandoning one-size-fits-all allopathic thinking improves outcomes
How estrogen, progesterone, and testosterone act on every organ system
The clinical impact of avoiding synthetic progestins
Brain and heart protection through estradiol: mechanisms and outcomes
Practical guidance for initiation, continuation, and tapering of therapy
Metabolic optimization and diabetes management essentials
Real-world observations from my clinical practice
Author
Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST
Links to my clinical insights:
https://dralexjimenez.com/
https://www.elpasochiropractorblog.com/
https://www.linkedin.com/in/dralexjimenez/
Rethinking Care: From Allopathic Symptom Control to Systems Optimization
As a functional and integrative clinician trained in chiropractic medicine, advanced practice nursing, and functional medicine, I have repeatedly seen how the allopathic model—treating a symptom with a medication—often misses root causes. Disease is not a normal state; homeostasis is. My goal is to help patients return to physiologic balance by understanding and correcting underlying disruptions in neuroendocrine-immune networks.
Key shifts I ask new clinicians to make:
Replace the impulse to suppress symptoms with a drive to analyze mechanisms.
Focus on restoring homeostasis: cellular signaling, mitochondrial function, vascular integrity, immune modulation, and biotransformation.
Embrace individualized protocols: age, metabolic status, comorbidities, genetics, and patient goals must inform hormones, nutrition, exercise, sleep, and stress strategies.
In practice, this philosophical pivot improves quality of life, reduces polypharmacy, and enhances long-term outcomes across cognitive, cardiovascular, musculoskeletal, and metabolic domains.
Clearing Space: Updating Knowledge and Refreshing Clinical Skills
For clinicians entering hormone optimization, the most empowering first step is to "clean up" old assumptions. Misinterpretations from earlier eras—especially around estrogen—still ripple through practice patterns today. I encourage continuous retraining and refreshers because:
New findings update risk-benefit calculations.
Hearing similar concepts from different experts catalyzes learning by reframing familiar ideas in new contexts.
Clinical experience makes evidence "click" when you revisit it after seeing patients.
In my own practice, with tens of thousands of procedures completed and patients ranging from adolescence to advanced age, I can attest that consistent follow-up and ongoing education profoundly improve outcomes. Year after year, clinicians report that revisiting core topics—receptors, dosing strategies, and risk stratification—makes them more confident and effective.
Hormone Receptors: Every Cell, Every System
One foundational truth reframes everything: hormone receptors are present on virtually every cell in the body. That includes estrogen receptors (ERα and ERβ), progesterone receptors (PR), and androgen receptors (AR) across the brain, heart, vasculature, bone, gut, immune cells, and more. This ubiquity explains why the narrow view—estrogen only for hot flashes, testosterone only for erectile function—is inadequate.
What receptor biology teaches us:
Specificity matters: Bioidentical hormones bind native receptors and elicit natural downstream signaling; synthetic progestins are structurally distinct and can act as antagonists within estrogen-responsive gene networks, blocking beneficial actions rather than supporting them (Santen et al., 2020; Prior, 2019).
Lipophilicity and distribution: Estradiol is lipophilic, crosses the blood-brain barrier, and engages nuclear and membrane receptors, modulating transcription and rapid signaling (Arevalo et al., 2015).
Systems-level impacts: ER signaling influences synaptic plasticity, microglial and astrocyte activation, vascular nitric oxide (NO) production, insulin sensitivity, cholesterol homeostasis, and bone remodeling.
The physiological reasoning:
Where there is a receptor, there is a functional need. Optimizing hormone availability in tissues enhances repair, resilience, and regulatory balance across interconnected systems.
Estrogen Beyond Hot Flashes: Brain, Bone, Gut, Immunity, Pain
A modern, evidence-based perspective shows estradiol (17β-estradiol) is not a “hot-flash drug.” It is a systems regulator with measurable impacts:
Brain and cognition
Neuroprotection: Estradiol reduces beta-amyloid deposition, decreases apoptosis, and bolsters synaptic plasticity and neurogenesis (Yao et al., 2012; Arevalo et al., 2015).
Cognition and executive function: Continuous combination therapy has been linked to improved cognitive performance among postmenopausal women compared with non-users, when carefully selected and dosed (Maki & Henderson, 2016).
Stroke mitigation: Estradiol modulates post-ischemic immune cascades, reduces excitotoxic injury, and improves neuronal survival signaling (Suzuki et al., 2007; Hurn & Brass, 2003).
Bone health
Tri-hormone involvement: Estrogen, progesterone, and testosterone receptors are present on osteoblasts, osteoclasts, and osteocytes, indicating synergistic roles in bone turnover and strength (Manolagas et al., 2013). Short courses of less than 5 years may be insufficient; consistent therapy shows greater preservation (Greendale et al., 2002).
Gut and biotransformation
The gut acts as an endocrine organ modulating estrogen metabolism through the estrobolome. Dysbiosis alters enterohepatic recirculation, influencing systemic estrogen availability and inflammatory tone (Plottel & Blaser, 2011).
Pain modulation
Estradiol regulates descending pain pathways, astrocyte/microglial activation, and central sensitization dynamics, reducing pain amplification in chronic pain states (Craft, 2007; Loyd & Murphy, 2014).
Why these effects hold clinically:
Estradiol's actions converge on inflammation resolution, mitochondrial function, vascular integrity, and neural plasticity—mechanisms central to aging and chronic disease.
Setting the Record Straight: WHI Revisited and Misconceptions
A core source of fear has been the conflation of all hormone therapies as having a single class effect—especially after the early reporting of the Women's Health Initiative (WHI). Modern re-analyses and follow-ups clarify:
Estrogen-alone arm (CEE) in women with prior hysterectomy showed reductions in breast cancer incidence and mortality, and benefits in cardiovascular and cognitive outcomes compared to placebo (Manson et al., 2013; Chlebowski et al., 2013).
The combined arm with medroxyprogesterone acetate (MPA) showed the most adverse signals. These outcomes should not be generalized to all forms of progesterone, especially bioidentical micronized progesterone, which exhibits different receptor dynamics and gene expression profiles (Santen et al., 2020; Prior, 2019).
Practice implications
Avoid extrapolating data from synthetic progestin-containing regimens to bioidentical protocols.
Consider estradiol with micronized progesterone for women with an intact uterus when indicated; progesterone protects the endometrium without blocking estradiol’s neuroprotective and cardiometabolic benefits.
Clinical rationale
The error was in assuming class equivalence; however, molecular pharmacology demonstrates that synthetic progestins and natural progesterone have different safety and efficacy profiles.
Individualized Duration: No Automatic Stop at Age 65
In 2017, the North American Menopause Society (NAMS) updated its guidance to affirm individualized decision-making regarding the type, dose, route, and duration of hormone therapy, emphasizing risk-benefit assessments rather than arbitrary age cutoffs (The 2017 hormone therapy position statement of The North American Menopause Society). Evidence does not support routine discontinuation based solely on age; initiation after age 60 can still confer benefits when risk is appropriately managed (Manson et al., 2013).
Key points for patient conversations
There is no universal "too old" threshold for considering estradiol; initiation later in life must be tailored to vascular, metabolic, and oncologic profiles.
Gradual tapering, if discontinuation is necessary, helps avoid vasomotor rebound, arrhythmias, and acute spikes in risk observed with abrupt discontinuation of certain oral synthetics (Hu et al., 2006).
Brain Imaging, Early Interventions, and Prevention Logic
Modern imaging and longitudinal data underscore that beta-amyloid accumulation and microvascular changes appear years before symptoms. Waiting for clinical decline is a missed opportunity. Estradiol's ability to:
Enhance synaptic resilience
Reduce neuroinflammation
Regulate cholesterol and glucose metabolism
As suggested earlier, appropriately dosed initiation yields stronger neuroprotective effects. In perimenopause, clinicians should monitor cognitive complaints, sleep disruption, vasomotor instability, and mood changes—often early warning flags of neuroendocrine transitions.
Mechanistic insight
Estradiol's modulation of ERK/AKT, BDNF, and mitochondrial biogenesis pathways supports neuronal survival and plasticity, explaining improved executive function and memory performance.
Cardiovascular Protection: Endothelium, Atherosclerosis, and Lipids
The heart mirrors the brain in its responsiveness to estradiol and androgens:
Endothelial NO production rises with estradiol signaling, improving vascular compliance and microcirculation (Mendelsohn & Karas, 2005).
Early initiation and continuation of estradiol slows the progression of subclinical atherosclerosis, with trials showing up to a 50% reduction in plaque progression rates compared with controls when therapy begins near menopause (Hodis et al., 2016).
Testosterone and estradiol together favor lean mass preservation, visceral fat reduction, and improvements in the lipid profile, supporting cardiometabolic health (Traish et al., 2011).
Why it works
Cardiovascular disease is largely inflammatory and metabolic, not simply due to excess cholesterol. Estradiol improves lipoprotein handling, glycemic control, and vascular repair, lowering all-cause mortality in multiple cohorts (Manson et al., 2013).
Men's Health: Do Not Block Estrogen Without Clear Indications
In men, estradiol is generated via aromatase from testosterone. That conversion is not a side-effect; it is central to:
Endothelial function
Bone density
Libido and erectile quality
Visceral fat regulation
Routine use of aromatase inhibitors (AIs) to suppress estradiol in men on testosterone therapy can undermine these benefits. Clinical observations from my practice show:
Stopping unnecessary AIs frequently restores erectile function, elevates mood, and reduces visceral adiposity.
Laboratory "expected ranges" for estradiol must be interpreted in the context of physiologic testosterone levels; a healthy, higher testosterone often implies proportionally higher estradiol via aromatization.
Evidence basis
Estradiol contributes directly to vascular health and metabolic balance in men, mirroring its benefits in women (Finkelstein et al., 2013; Rochira & Carani, 2009). Blocking estradiol without clear, symptomatic hyperestrogenic indications is counterproductive.
Breast Cancer: Nuance, Risk, and Modern Data
One of the biggest fears among women is that estrogen causes breast cancer. Contemporary data demand a nuanced view:
Estrogen therapy, especially estradiol-only in hysterectomized women, has been associated with reduced breast cancer incidence and mortality in long-term follow-up compared to placebo (Chlebowski et al., 2013).
Synthetic progestins (e.g., MPA) have been implicated in adverse breast outcomes; micronized progesterone shows a different profile with less evidence of risk amplification (Santen et al., 2020; Prior, 2019).
Post-treatment quality of life in breast cancer survivors is a legitimate clinical outcome; carefully individualized hormone strategies must weigh recurrence risks, receptor status, and alternative symptom management (Santen et al., 2020).
Clinical reasoning
Shift focus toward metabolic and inflammatory indicators that drive carcinogenesis. Loss of estradiol can worsen insulin resistance, visceral adiposity, and chronic inflammation, each linked to higher cancer risk.
Some cohorts and reviews show that estradiol does not increase recurrence in carefully selected survivors; however, this requires meticulous case-by-case assessment aligned with oncology guidance.
Patient counseling
The conversation should emphasize data that distinguish bioidentical hormones from synthetic progestins and estradiol from conjugated estrogens plus synthetic progestins. The more precise the pharmacology, the clearer the risk-benefit picture.
Recommended reading
The book Estrogen Matters provides a detailed, accessible overview by an oncologist who re-examined prevailing beliefs after witnessing real-world quality-of-life consequences.
Afternoon Focus: Metabolic Health and Diabetes Management
After laying hormone fundamentals, we move into metabolic optimization—the core of preventing chronic disease.
Key clinical priorities
Assess and target insulin resistance using fasting glucose, fasting insulin, HOMA-IR, HbA1c, and continuous glucose monitoring when available.
Address visceral adiposity through nutrition, resistance training, sleep restoration, and stress modulation; estradiol supports visceral fat loss, while testosterone preserves lean mass.
Correct micronutrient insufficiencies that impair insulin signaling (e.g., magnesium, vitamin D) and consider gut microbiome status impacting glycemic variability.
Diabetes care nuts and bolts
Lifestyle-first care: low-glycemic, nutrient-dense diet, individualized carbohydrate tolerance, protein sufficiency, and progressive resistance training to improve GLUT4 translocation and mitochondrial efficiency.
Pharmacologic adjuncts when needed: metformin for hepatic glucose output and mitochondrial health; GLP-1 receptor agonists when appropriate for satiety and weight loss; always integrate with behavioral strategies to avoid sole reliance on medications.
Hormone crosstalk: Estradiol enhances insulin sensitivity, reduces hepatic steatosis, and improves vascular compliance; testosterone supports muscle mass, indirectly improving glycemic control.
Clinical observation from the El Paso practice
Patients who pair bioidentical hormone optimization with structured lifestyle protocols experience faster improvements in glycemic indices, lipids, and blood pressure, as well as better sleep and mood—key mediators of adherence and long-term success.
Community-specific factors (shift work, cross-border diet patterns, stress) require cultural tailoring. I often adjust meal timing strategies and incorporate family-based interventions to improve sustainability.
Practical Protocols: Initiation, Dosing, Route, and Monitoring
Individualize therapy through:
Baseline assessment: medical history, family history, vascular risk stratification, breast imaging where indicated, bone density, cognitive screening, sleep assessment, and metabolic panels.
Initiation timing: Perimenopausal or early postmenopausal starts often yield better neurovascular outcomes, but later initiation remains beneficial with careful titration.
Routes and formulations:
Transdermal estradiol offers steady delivery with lower thrombotic risk versus some oral routes.
Micronized progesterone to protect the endometrium without obstructing estradiol's neuroprotective signaling.
Testosterone for women in low physiologic doses can improve libido, energy, and lean mass; monitor levels and symptoms closely.
Monitoring:
Symptom tracking: hot flashes, sleep, mood, cognition, libido, joint pain, and exercise recovery.
Biomarkers: estradiol, progesterone, total and free testosterone as appropriate, SHBG, fasting glucose/insulin, HbA1c, lipids, inflammatory markers (hs-CRP), and vitamin D.
Tapering and discontinuation:
Avoid abrupt stops; taper gradually to reduce vasomotor relapse and arrhythmic risk.
Reassess annually with shared decision-making.
Rationale
Matching molecule-to-receptor biology with the route to risk profile maximizes benefit and minimizes harm. Continuous assessment ensures therapy adapts to life changes and patient goals.
Clinician Development: Why Refreshers Matter
I encourage clinicians to return to these topics regularly. As I have observed with colleagues who revisit training year after year, you will:
Hear familiar ideas voiced through new experiences.
Integrate more nuance as your patient panel diversifies.
Strengthen your risk-benefit analysis and protocol personalization.
This cycle of practice and study sharpens decision-making and elevates the quality of care.
Summary: Actionable Takeaways
Replace symptom suppression with systems optimization.
Recognize that estradiol, progesterone, and testosterone act across all organ systems via ubiquitous receptors.
Distinguish bioidentical hormones from synthetic progestins; do not generalize WHI combined-arm risks to all therapies.
Consider transdermal estradiol plus micronized progesterone for women with a uterus; employ individualized duration rather than automatic discontinuation at age 65.
Embrace early initiation near menopause for stronger neurovascular benefits; later initiation can still be valuable with careful risk stratification.
Do not routinely block estradiol in men; aromatization supports vascular, metabolic, bone, and sexual health.
Integrate metabolic optimization and diabetes management with hormone therapy to reduce chronic disease burden.
Taper carefully if discontinuation is necessary; avoid abrupt withdrawal.
Maintain ongoing education; repeated exposure to updated literature and peer experiences enhances clinical proficiency.
References
The 2017 hormone therapy position statement of The North American Menopause Society. (2017). Menopause, 24(7), 728–753. https://doi.org/10.1097/GME.0000000000000921
Estrogen therapy and long-term health outcomes: The Women’s Health Initiative follow-up. Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2013). JAMA Internal Medicine, 173(15), 1468–1477. https://doi.org/10.1001/jamainternmed.2013.7721
Breast cancer incidence and mortality with estrogen therapy in WHI. Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2013). JAMA Internal Medicine, 173(15), 1461–1467. https://doi.org/10.1001/jamainternmed.2013.13013
Estrogen actions in the brain: Rapid signaling and gene regulation. Arevalo, M.-A., Azcoitia, I., & Garcia-Segura, L. M. (2015). Pharmacology Biochemistry and Behavior, 133, 3–16. https://doi.org/10.1016/j.pbb.2015.03.009
Neuroprotective mechanisms of estradiol in Alzheimer’s disease models. Yao, J., et al. (2012). Brain Research, 1483, 88–96. https://doi.org/10.1016/j.brainres.2012.09.034
Sex differences in stroke and estrogen neuroprotection. Hurn, P. D., & Brass, L. M. (2003). American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 285(2), R277–R279. https://doi.org/10.1152/ajpregu.00347.2003
Estradiol and ischemic brain injury modulation. Suzuki, S., et al. (2007). Basic Research in Cardiology, 102(4), 326–335. https://doi.org/10.1007/s00395-007-0668-0
Hormones and bone remodeling: Interplay of sex steroids. Manolagas, S. C., et al. (2013). Endocrine Reviews, 34(5), 626–667. https://doi.org/10.1210/er.2012-1072
Atherosclerosis progression and early estradiol therapy: ELITE trial. Hodis, H. N., et al. (2016). Circulation, 134(20), 1435–1445. https://doi.org/10.1161/CIRCULATIONAHA.115.018206
Estrogens and endothelial function. Mendelsohn, M. E., & Karas, R. H. (2005). Circulation, 111(10), 1317–1331. https://doi.org/10.1161/01.CIR.0000159385.06477.5F
Testosterone, estradiol, and body composition in men. Finkelstein, J. S., et al. (2013). New England Journal of Medicine, 369, 1011–1022. https://doi.org/10.1056/NEJMoa1200625
Aromatase, estradiol, and male health. Rochira, V., & Carani, C. (2009). Journal of Clinical Endocrinology & Metabolism, 94(6), 1913–1915. https://doi.org/10.1210/jc.2009-0664
Abrupt cessation of hormone therapy and cardiovascular events. Hu, F. B., et al. (2006). Circulation, 113(26), 2909–2917. https://doi.org/10.1161/CIRCULATIONAHA.105.582759
Synthetic progestins vs. micronized progesterone: Differential effects. Santen, R. J., et al. (2020). Journal of Clinical Endocrinology & Metabolism, 105(12), e4481–e4505. https://doi.org/10.1210/clinem/dgaa730
Progesterone physiology and clinical implications in women. Prior, J. C. (2019). Archives of Women's Mental Health, 22(2), 173–180. https://doi.org/10.1007/s00737-018-0931-0
Estradiol and the gut estrobolome. Plottel, C. S., & Blaser, M. J. (2011). American Journal of Gastroenterology, 106, 994–1002. https://doi.org/10.1038/ajg.2010.139
Pain modulation by gonadal hormones. Craft, R. M. (2007). Pharmacology Biochemistry and Behavior, 86(2), 1–20. https://doi.org/10.1016/j.pbb.2006.11.009
Sex differences in pain: Glia and hormones. Loyd, D. R., & Murphy, A. Z. (2014). Nature Reviews Neuroscience, 15, 29–41. https://doi.org/10.1038/nrn2049
Testosterone therapy and cardiometabolic profiles. Traish, A. M., et al. (2011). The Journal of Sexual Medicine, 8(1), 177–212. https://doi.org/10.1111/j.1743-6109.2010.01945.x
Estrogen Matters. Bluming, A., & Tavris, C. (2018). Basic Books.
The information herein is not intended to replace a one-on-one relationship with a qualified healthcare professional or licensed physician and is not medical advice. We encourage you to make healthcare decisions based on your research and partnership with a qualified healthcare professional. Our information scope is limited to chiropractic, musculoskeletal, and physical medicine, as well as wellness, sensitive health issues, and functional medicine articles, topics, and discussions. We provide and facilitate clinical collaboration with specialists across disciplines. Each specialist is governed by their professional scope of practice and the jurisdiction in which they are licensed. We utilize functional health and wellness protocols to treat and support care for musculoskeletal injuries or disorders. Our videos, posts, topics, subjects, and insights cover clinical matters and issues that directly or indirectly support our clinical scope of practice. Our office has made a reasonable effort to provide supportive citations and identify relevant research studies for our posts. We provide copies of supporting research studies upon request to regulatory boards and the public.
We are here to help you and your family.
Blessings
Dr. Alex Jimenez, DC, MSACP, APRN, FNP-BC*, CCST, IFMCP, CFMP, ATN
email: coach@elpasofunctionalmedicine.com
Multidisciplinary Licensing & Board Certifications:
Licensed as a Doctor of Chiropractic (DC) in Texas & New Mexico*
Texas DC License #: TX5807, Verified: TX5807
New Mexico DC License #: NM-DC2182, Verified: NM-DC2182
Multi-State Advanced Practice Registered Nurse (APRN*) in Texas & Multi-States
Multi-State Compact APRN License by Endorsement (42 States)
Texas APRN License #: 1191402, Verified: 1191402 *
Florida APRN License #: 11043890, Verified: APRN11043890 *
New York APRN License #: N25929, Verified: APRN-N25929*
License Verification Link: Nursys License Verifier
* Prescriptive Authority Authorized
ANCC FNP-BC: Board Certified Nurse Practitioner*
Compact Status: Multi-State License: Authorized to Practice in 40 States*
Graduate with Honors: ICHS: MSN-FNP (Family Nurse Practitioner Program)
Degree Granted. Master's in Family Practice MSN Diploma (Cum Laude)
Dr. Alex Jimenez, DC, APRN, FNP-BC*, CFMP, IFMCP, ATN, CCST
My Digital Business Card
